CLINICALLY RELEVANT SUBGROUP ANALYSIS FROM THE RANDOMIZED PHASE 3 EPCORE FL-1 TRIAL: TREATMENT EFFECT OF EPCORITAMAB WITH LENALIDOMIDE AND RITUXIMAB (R²) IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (SIE 2026) - Oct 6, 2026 - Abstract #DP057; Pres time: Sep 21, 2026; 07:00 PM - 08:00 PM; Location: AREA POSTER; "Clinically meaningful improvements were observed across lower-risk disease features and lower Len RDI, supporting E+R² as an option for a diverse R²-eligible population. The EPCORE FL-1 findings position fixed-duration E+R² as a new bench- mark standard of care for a broad population of pts with R/R FL in 2L+ treatment."
Clinical • P3 data • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • CD20
|
|
C. Patti1; M. Nijland2; L. Falchi3; K. Linton4; N. Goldschmidt5; B. Tessoulin6; D. Belada7; S. Ma8; J. Schmidt Filho9; J. Shen10; J. Miguel Bergua Burgues11; U. Vitolo12; M. Kwiatek13; L. Ysebaert14; T. P. Vassilakopoulos15; A. Egle16; J-F. Larouche17; G. Sunkersett18; M. A. Rocco19; N. Mukherjee18; R. Moskal18; Y. Li18; B. Elliott20; F. Morschhauser21
|